The ketogenic diet alters the hypoxic response and affects expression of proteins associated with angiogenesis, invasive potential and vascular permeability in a mouse glioma model

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Woolf, Eric C ^a,b   Curley, Kara L ^a   Liu, Qingwei ^a   Turner, Gregory H ^a   Charlton, Julie A ^a   Preul, Mark C ^a   Scheck, Adrienne C ^a,b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; AQUAPORIN 1; AQUAPORIN 4; CARBONATE DEHYDRATASE IX; CONTRAST MEDIUM; GELATINASE A; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KETONE; OCCLUDIN; PROTEIN ZO1; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VIMENTIN; AQP4 PROTEIN, MOUSE; CAR9 PROTEIN, MOUSE; CARBONATE DEHYDRATASE; MESSENGER RNA; TJP1 PROTEIN, MOUSE; TUMOR MARKER; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD VESSEL PERMEABILITY; BODY WEIGHT; CANCER INHIBITION; CANCER SURVIVAL; CELL HYPOXIA; CONTROLLED STUDY; EDEMA; EX VIVO STUDY; FEMALE; GLIOBLASTOMA; GLUCOSE BLOOD LEVEL; IN VIVO STUDY; KETOGENIC DIET; MICROVASCULATURE; MOUSE; NONHUMAN; PERITUMORAL EDEMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; BRAIN TUMOR; C57BL MOUSE; CELL MEMBRANE PERMEABILITY; DIET THERAPY; DISEASE MODEL; ENZYME IMMUNOASSAY; GENETICS; GLIOMA; HYPOXIA; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULARIZATION;

ANIMALIA;

ANIMALS; AQUAPORIN 4; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CARBONIC ANHYDRASE IX; CARBONIC ANHYDRASES; CELL MEMBRANE PERMEABILITY; DISEASE MODELS, ANIMAL; FEMALE; GLIOMA; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOENZYME TECHNIQUES; KETOGENIC DIET; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED C57BL; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; ZONULA OCCLUDENS-1 PROTEIN;

EID: 84939123198     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0130357     Document Type: Article

References (57)

1. Olar A, Aldape KD (2014) Using the molecular classification of glioblastoma to inform personalized treatment. J Pathol 232: 165-177. doi:10.1002/path.4282 PMID: 24114756.
2. Warburg O, Wind F, Negelein E (1927) Themetabolism of tumors in the body. J Gen Physiol 8: 519-530. PMID: 19872213.
3. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144: 646-674. doi:10.1016/j.cell.2011.02.013 PMID: 21376230.
4. Woolf EC, Scheck AC (2012) Metabolism and glioma therapy. CNS Oncol 1: 7-10. doi:10.2217/cns.12.9 PMID: 25054292.
5. Woolf EC, Scheck AC (2015) The ketogenic diet for the treatment of malignant glioma. J Lipid Res 56: 5-10. doi:10.1194/jlr.R046797 PMID: 24503133.
6. Stafford P, Abdelwahab MG, Kim DY, Preul MC, Rho JM, Scheck AC (2010) The ketogenic diet reverses gene expression patterns and reduces reactive oxygen species levels when used as an adjuvant therapy for glioma. Nutr Metab (Lond) 7: 74. doi:10.1186/1743-7075-7-74 PMID: 20831808.
7. Fruehauf JP, Meyskens FL Jr. (2007) Reactive oxygen species: A breath of life or death? Clin Cancer Res 13: 789-794. PMID: 17289868.
8. Weinberg F, Chandel NS (2009) Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci 66: 3663-3673. doi:10.1007/s00018-009-0099-y PMID: 19629388.
9. Abdelwahab MG, Fenton KE, Preul MC, Rho JM, Lynch A, Stafford P, Scheck AC (2012) The ketogenic diet is an effective adjuvant to radiation therapy for the treatment of malignant glioma. PLoS ONE 7: E36197. doi:10.1371/journal.pone.0036197 PMID: 22563484.
10. Semenza GL (2009) Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 19: 12-16. doi:10.1016/j.semcancer.2008.11.009 PMID: 19114105.
11. Yang L, Lin C, Wang L, Guo H, Wang X (2012) Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp Cell Res 318: 2417-2426. doi:10.1016/j.yexcr.2012.07.017 PMID: 22906859.
12. Abdelwahab MG, Sankar T, Preul MC, Scheck AC (2011) Intracranial Implantation with Subsequent In Vivo Bioluminescent Imaging of Murine Gliomas. JOVE 57: E3403. doi:10.3791/3403 PMID: 22158303.
13. Mulrooney TJ, Marsh J, Urits I, Seyfried TN, Mukherjee P (2011) Influence of caloric restriction on constitutive expression of NF-kappaB in an experimental mouse astrocytoma. PLoS ONE 6: E18085. doi:10.1371/journal.pone.0018085 PMID: 21479220.
14. Schnell SA, Staines WA, Wessendorf MW (1999) Reduction of lipofuscin-like autofluorescence in fluorescently labeled tissue. J Histochem Cytochem 47: 719-730. PMID: 10330448.
15. Kaur B, Khwaja FW, Severson EA, Matheny SL, Brat DJ, Van Meir EG (2005) Hypoxia and the hypoxia- inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 7: 134-153. PMID: 15831232.
16. Proescholdt MA, Merrill MJ, Stoerr EM, Lohmeier A, Pohl F, Brawanski A (2012) Function of carbonic anhydrase IX in glioblastoma multiforme. Neuro Oncol 14: 1357-1366. doi:10.1093/neuonc/nos216 PMID: 23074198.
17. Jain RK (2008) Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat Rev Cancer 8: 309-316. doi:10.1038/nrc2346 PMID: 18337733.
18. Navis AC, Bourgonje A, Wesseling P, Wright A, Hendriks W, Verrijp K, van der Laak JA, Heerschap A, Leenders WP (2013) Effects of dual targeting of tumor cells and stroma in human glioblastoma xenografts with a tyrosine kinase inhibitor against c-MET and VEGFR2. PLoS ONE 8: E58262. doi:10.1371/journal.pone.0058262 PMID: 23484006.
19. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, hicklin DJ, Fukumura D, di TE, Munn LL, Jain RK (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: Role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6: 553-563. PMID: 15607960.
20. Li X, Kumar A, Zhang F, Lee C, Tang Z (2012) Complicated life, complicated VEGF-B. Trends Mol Med 18: 119-127. doi:10.1016/j.molmed.2011.11.006 PMID: 22178229.
21. Dai W, Zeller C, Masrour N, Siddiqui N, Paul J, Brown R (2013) Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer. Clin Cancer Res 19: 5788-5797. doi:10.1158/1078-0432.CCR-13-1217 PMID: 23965899.
22. Reardon DA, Herndon JE, Peters K, Desjardins A, Coan A, Lou E, Sumrall A, Turner S, Sathornsumetee S, Rich JN, Boulton S, Lipp ES, Friedman HS, Vredenburgh JJ (2012) Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol 107: 213-221. doi:10.1007/s11060-011-0740-0 PMID: 21997879.
23. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy- Temozolomide for newly diagnosed glioblastoma. N Engl J Med 370: 709-722. doi:10.1056/NEJMoa1308345 PMID: 24552318.
24. Hu YL, DeLay M, Jahangiri A, Molinaro AM, Rose SD, Carbonell WS, Aghi MK (2012) Hypoxia-induced autophagy promotes tumor cell survival and adaptation to antiangiogenic treatment in glioblastoma. Cancer Res 72: 1773-1783. doi:10.1158/0008-5472.CAN-11-3831 PMID: 22447568.
25. Ishihara H, Kubota H, Lindberg RL, Leppert D, Gloor SM, Errede M, Virgintino D, Fontana A, Yonekawa Y, Frei K (2008) Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta2 involves matrix metalloproteinases and tight junction proteins. J Neuropathol Exp Neurol 67: 435-448. doi:10.1097/NEN.0b013e31816fd622 PMID: 18431253.
26. Badiga AV, Chetty C, Kesanakurti D, Are D, Gujrati M, Klopfenstein JD, Dinh DH, Rao JS (2011) MMP- 2 siRNA inhibits radiation-enhanced invasiveness in glioma cells. PLoS ONE 6: E20614. doi:10.1371/journal.pone.0020614 PMID: 21698233.
27. Myung JK, Choi SA, Kim SK, Wang KC, Park SH (2014) Snail plays an oncogenic role in glioblastoma by promoting epithelial mesenchymal transition. Int J Clin Exp Pathol 7: 1977-1987. PMID: 24966907.
28. Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF (2006) Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res 4: 607-619. PMID: 16966431.
29. Jain R, Narang J, Gutierrez J, Schultz LR, Scarpace L, Rosenblum M, Mikkelsen T, Rock JP (2011) Correlation of immunohistologic and perfusion vascular parameters with MR contrast enhancement using image-guided biopsy specimens in gliomas. Acad Radiol 2011 Aug 18: 955-962. doi:10.1016/j.acra.2011.04.003 PMID: 21718954.
30. Azzi S, Hebda JK, Gavard J (2013) Vascular permeability and drug delivery in cancers. Front Oncol 3: 211. doi:10.3389/fonc.2013.00211 PMID: 23967403.
31. de GJ, Reardon DA, Batchelor TT (2013) Antiangiogenic therapy for glioblastoma. Am Soc Clin Oncol Educ Book 2013: 71-78.
32. Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA (2009) Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol 27: 1082-1086. doi:10.1200/JCO.2008.19.1098 PMID: 19139429.
33. McGirt MJ, Chaichana KL, Gathinji M, Attenello F, Than K, Ruiz AJ, Olivi A, Quinones-Hinojosa A (2008) Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery 63: 286-291. doi:10.1227/01.NEU.0000315282.61035.48 PMID: 18797358.
34. Mayer A, Vaupel P, Struss HG, Giese A, Stockinger M, Schmidberger H (2014) Strong adverse prognostic impact of hyperglycemic episodes during adjuvant chemoradiotherapy of glioblastoma multiforme. Strahlenther Onkol 190: 933-938. doi:10.1007/s00066-014-0696-z PMID: 24938515.
35. Culver C, Sundqvist A, Mudie S, Melvin A, Xirodimas D, Rocha S (2010)Mechanism of hypoxia-induced NF-kappaB. Mol Cell Biol 30: 4901-4921. doi:10.1128/MCB.00409-10 PMID: 20696840.
36. Nogueira L, Ruiz-Ontanon P, Vazquez-Barquero A, Moris F, Fernandez-Luna JL (2011) The NFkappaB pathway: A therapeutic target in glioblastoma. Oncotarget 2: 646-653. PMID: 21896960.
37. Ma J, Wang P, Liu Y, Zhao L, Li Z, Xue Y (2014) Kruppel-like factor 4 regulates blood-tumor barrier permeability via ZO-1, occludin and claudin-5. J Cell Physiol 229: 916-926. doi:10.1002/jcp.24523 PMID: 24318462.
38. Fischer S, Wobben M, Marti HH, Renz D, Schaper W(2002) Hypoxia-induced hyperpermeability in brain microvessel endothelial cells involves VEGF-mediated changes in the expression of zonula occludens-1. Microvasc Res 63: 70-80. PMID: 11749074.
39. Higashida T, Kreipke CW, Rafols JA, Peng C, Schafer S, Schafer P, Ding JY, Dornbos D III, Li X, Guthikonda M, Rossi NF, Ding Y (2011) The role of hypoxia-inducible factor-1alpha, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury. J Neurosurg 114: 92-101. doi:10.3171/2010.6.JNS10207 PMID: 20617879.
40. Ribatti D, Ranieri G, Annese T, Nico B (2014) Aquaporins in cancer. Biochim Biophys Acta 1840: 1550-1553. doi:10.1016/j.bbagen.2013.09.025 PMID: 24064112.
41. Yang L, Wang X, Zhen S, Zhang S, Kang D, Lin Z (2012) Aquaporin-4 upregulated expression in glioma tissue is a reaction to glioma-associated edema induced by vascular endothelial growth factor. Oncol Rep 28: 1633-1638. doi:10.3892/or.2012.1973PMID: 22922737.
42. Liu D, Martin V, Fueyo J, Lee OH, Xu J, Cortes-Santiago N, Alonso MM, Aldape K, Colman H, Gomez- Manzano C (2010) Tie2/TEK modulates the interaction of glioma and brain tumor stem cells with endothelial cells and promotes an invasive phenotype. Oncotarget 1: 700-709. PMID: 21321379.
43. Raghu H, Nalla AK, Gondi CS, Gujrati M, Dinh DH, Rao JS (2012) uPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells. Mol Oncol 6: 33-47. doi:10.1016/j.molonc.2011.11.008 PMID: 22177802.
44. Raghu H, Lakka SS, Gondi CS, Mohanam S, Dinh DH, Gujrati M, Rao JS (2010) Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines. PLoS ONE 5: E12458. doi:10.1371/journal.pone.0012458PMID:20805979.
45. Machein MR, Knedla A, Knoth R, Wagner S, Neuschl E, Plate KH (2004) Angiopoietin-1 promotes tumor angiogenesis in a rat glioma model. Am J Pathol 165: 1557-1570. PMID: 15509526.
46. Zadeh G, Koushan K, Pillo L, Shannon P, Guha A (2004) Role of Ang1 and its interaction with VEGF-A in astrocytomas. J Neuropathol Exp Neurol 63: 978-989. PMID: 15453096.
47. Zadeh G, Reti R, Koushan K, Baoping Q, Shannon P, Guha A (2005) Regulation of the pathological vasculature of malignant astrocytomas by angiopoietin-1. Neoplasia 7: 1081-1090. PMID: 16354591.
48. Jahangiri A, Aghi MK, Carbonell WS (2014) beta1 Integrin: Critical Path to Antiangiogenic Therapy Resistance and Beyond. Cancer Res 74: 3-7. doi:10.1158/0008-5472.CAN-13-1742 PMID: 24327727.
49. Carbonell WS, DeLay M, Jahangiri A, Park CC, Aghi MK (2013) beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma. Cancer Res 73: 3145-3154. doi:10.1158/0008-5472.CAN-13-0011 PMID: 23644530.
50. Crocker M, Ashley S, Giddings I, Petrik V, Hardcastle A, Aherne W, Pearson A, Bell BA, Zacharoulis S, Papadopoulos MC (2011) Serum angiogenic profile of patients with glioblastoma identifies distinct tumor subtypes and shows that TIMP-1 is a prognostic factor. Neuro Oncol 13: 99-108. doi:10.1093/neuonc/noq170 PMID: 21163810.
51. Lucio-Eterovic AK, Piao Y, de Groot JF (2009) Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res 15: 4589-4599. doi:10.1158/1078-0432.CCR-09-0575 PMID: 19567589.
52. Rous P (1914) The influence of diet on transplanted and spontaneous mouse tumors. J Exp Med 20: 433-451. PMID: 19867833.
53. Seyfried TN, Flores R, Poff AM, D'Agostino DP (2014) Cancer as a Metabolic Disease: Implications for Novel Therapeutics. Carcinogenesis 35: 515-527. doi:10.1093/carcin/bgt480 PMID: 24343361.
54. Urits I, Mukherjee P, Meidenbauer J, Seyfried TN (2012) Dietary restriction promotes vessel maturation in a mouse astrocytoma. J Oncol 2012: 264039. doi:10.1155/2012/264039 PMID: 22253625.
55. Jiang YS, Wang FR (2013) Caloric restriction reduces edema and prolongs survival in a mouse glioma model. J Neurooncol 114: 25-32. doi:10.1007/s11060-013-1154-y PMID: 23703297.
56. Kossoff EH, Wang HS (2013) Dietary therapies for epilepsy. Biomed J 36: 2-8. doi:10.4103/2319-4170.107152 PMID: 23515147.
57. Zhou W, Mukherjee P, Kiebish MA, Markis WT, Mantis JG, Seyfried TN (2007) The calorically restricted ketogenic diet, an effective alternative therapy for malignant brain cancer. Nutr Metab (Lond) 4:5: 5. PMID: 17313687.